INTRODUCTION
Diabetes Mellitus (DM) is a chronic metabolic disorder, characterized by a state of insulin deficiency that leads to a rise in glycemia (Gupta et al., 2005) , initially involving changes in carbohydrate metabolism and secondarily of lipids and proteins (Fontes, 2002; Negri, 2005) .
The most common symptoms observed in type I diabetes patients are polydipsy, polyuria, glycosuria, weakness with no apparent cause, and slow healing of wounds (Fontes, 2002) . The levels of glycemia and insulinemia must be controlled in order to avoid later complications of diabetes, such as atherosclerosis, hypertension, hypertriglyceridemia, hypercholesterolemia, myocardial infarction, ischemic attacks, impotence, retinopathy, nephropathy, etc (Stadler et al., 2003) .
As yet there are no effective therapies to cure diabetes (Maiti et al., 2004) . Many hypoglycemiant agents, such as the biguanides and sulfonylureas, are used alone or together with insulin to treat this disease. However, these medications can cause serious side effects (Hwang et al., 2005) , motivating a search for safer, more efficacious agents to control diabetes.
In recent years, interest has increased in using natural products for pharmacological purposes, as a form of complementary or replacement therapy. Particularly in the case of diabetes, published reports show that numerous extracts obtained from plants are effective in reducing glycemia, causing fewer side effects and with lower cost than the usual antidiabetic agents (Gupta et al., 2005) .
The majority of the plants that are used in popular medicine for treatment of diabetes have been shown to possess biologically active chemical constituents (alkaloids, carbohydrates, cumarins, flavonoids, terpenoids, phenolic substances, and other constituents) that can be used as new hypoglycemiant agents (Marles, Farnsworth, 1995; Gupta et al., 2005; Negri, 2005) .
Yacon is a plant native to the Andes, a species of the family Asteraceae (Compositae), with the botanical name Smallanthus sonchifolius. Morphologically, it is a perennial herb 1.5 to 3.0 m in height, with a root system composed of 4 to 20 oval or fusiform, fleshy tubers. The aerial part is formed by large leaves and flowers with yellow, radially arranged petals (Grau, Rea, 1997) .
Several studies have shown that the leaves of this plant possess different biological effects, among them inhibition of migration of polymorphonuclear leucocytes (Schorr, 2005) , immunomodulation (Lebeda et al., 2003; Valentová and Ulrichová, 2003) , antioxidant, and cytoprotector (Valentová et al., 2005) effects. In addition, studies have reported that tea made from an infusion of yacon leaves reduces glycemia and increases the concentration of insulin in the plasma of diabetic rats (Aybar et al., 2001) . Valentová et al. ( , 2004 observed that a yacon extract reduced the proportion of glucose in cultures of hepatocytes, acting in a manner similar to insulin.
Phytochemical studies have demonstrated that yacon leaves and stems are rich in proteins and phenolic compounds, such as caffeine, chlorogenic acid, ferulic acid, and flavonoids such as quercetin . The roots of the plant contain fructose, glucose, and fructooligosaccharides (inulin type), that can act as prebiotics, since after fermentation they favor the development of the bacterial flora (Pedreschi et al., 2003) .
Considering the increasing use of yacon in popular medicine, the present series of studies evaluated the effect of crude extracts of yacon leaves, obtained in different ways, on glycemia in diabetic and nondiabetic animals. The acute toxicity of the extract and the effect of the treatment on the levels of creatinine and the activity of certain enzymes on the plasma of the animals were also evaluated.
MATERIAL AND METHODS

Animals
The experiments were done using male Wistar rats weighing 180 to 220 g, and male and female Swiss mice weighing 20 to 25 g. The animals were maintained in controlled temperature (±22 ºC) and a 12-hour dark-light cycle, with balanced food and free access to water. The protocol for these experiments was approved by the Committee on Experimental Animal Ethics of the State University of Maringá, under number 014/2003.
Preparation of crude extracts
The extracts were prepared in three forms, from yacon leaves acquired from Takashi Kakihara Ltda., Capão Bonito, São Paulo, collected in December 2003. A voucher specimen was deposited at the Herbarium of the University of Maringá under number HUEM 13021. The crude extracts were obtained from 10% (w/w) solutions, by maceration with water at ambient temperature (cold extraction -Y C ) or by infusion in boiling water until the solution cooled (hot extraction -Y H ). The hydro-ethanolic extract (Y E ) was obtained from a 10% (w/w) solution with 70% ethanol, shaken mechanically for 5 hours. Next, the extracts were filtered, slowly evaporated to remove the solvent, lyophilized, and stored at -20 ºC. For the assays, the extracts of yacon leaves were diluted in water immediately before use.
Induction of diabetes
Diabetes was induced in rats fasted for 15 hours by intraperitoneal injection of streptozotocin (STZ), 50 mg/kg body weight, dissolved in 0.1 M citrate buffer (pH 4.6) (Brosky, Logothelopoulos, 1969) . After 48 h, blood was collected from a small incision made at the distal extremity of the fed animal's tail, for determination of glycemia. Rats with glycemia above 250 mg/dL were included in the study.
Treatment of animals
The crude extracts of yacon leaves (400 mg/kg body weight) or water were administered by the oral route (gavage), in a single daily dose at 9:00 h in the morning, in diabetic and nondiabetic rats. According to the experiment, the treatment was administered for different periods (3, 7, 10 or 14 days).
Collection of blood
At the end of the experimental period, the rats were fasted for 15 h and then anesthetized (ketamine and xylazine 1:1). Blood samples were collected from the inferior vena cava blood in heparinized tubes. The blood samples were centrifuged at 2500 rpm for 10 min, and the plasma was separated.
Effect of the hydro-ethanolic extract of yacon on glucose and creatinine in the plasma
The concentration of glucose was determined in aliquots of plasma (10 µL), using the glucose-oxidase colorimetric enzyme method (Gold Analisa ® ). The concentration of creatinine in the plasma was determined by a colorimetric enzyme method using Gold Analisa ® commercial kits.
Effect of hydro-ethanolic extract of yacon on consumption of food and water, volume of urine, and body weight of diabetic and nondiabetic rats
Groups of diabetic and nondiabetic animals were maintained in metabolic cages for 14 days, under treatment with the hydro-ethanolic extract of yacon, or water. The consumption of food and water, volume of urine, and body weight of these animals were evaluated daily.
Effect of hydro-ethanolic extract of yacon on the elevation of amylose-induced glycemia
Groups of nondiabetic rats fasted for 15 h received acarbose (10 mg/kg body weight), hydro-ethanolic extract of yacon (400 mg/kg), or water, and subsequently received, orally, a solution of amylose (500 mg/mL), at a dose of 1 g/kg body weight. After 30 min, their blood was collected for determination of glycemia (Galletto et al., 2004) .
Effect of the hydro-ethanolic extract of yacon on the elevation of glucose-induced glycemia
Groups of non-diabetic rats fasted for 15 h received hydro-ethanolic extracts of yacon (400 mg/kg body weight), or water, and then received orally, a solution of 50% glucose (1g/kg body weight). After 15, 30, 60, and 120 min, blood was collected for determination of glycemia (Zaahkouk et al., 2003) .
Effect of hydro-ethanolic of yacon on the activity of plasma phosphatase and transaminases
The activity of alkaline phosphatase (ALP), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) was determined in the plasma of diabetic and nondiabetic animals, by the colorimetric-kinetic method, using a commercial kit (Gold Analisa ® ). The animals were orally treated with the hydro-ethanolic extract of yacon (Y E ), at the dose of 400 mg/kg, or with water, for 14 days. On day 15, the animals, fasted for 15 h, were anesthetized (ketamine and xylazine 1:1), for collection of blood which was used in the determinations.
Acute toxicity (LD 50 )
Male and female mice fasted were orally administered with the hydro-ethanolic extract of yacon. Doses were increased progressively for the determination of the Lethal Dose (LD 50 ). The animals (n=10) were observed for 7 days, following treatment; food and water were provided throughout the experiment.
Statistical analysis
The statistical analysis of the data was done using GraphPad Prism ® (Graphpad Software Inc, Microsoft Corp.). The results were expressed as mean ± standard error of the mean, and were analyzed using Student's t test for comparison of two means, or analysis of variance (ANOVA followed by Tukey's test) for multiple comparisons. P<0.05 was considered the criterion for significance.
RESULTS
Effect of extracts of yacon (Y C , Y H and Y E ) on glycemia in diabetic and nondiabetic rats
The effect of the extracts of yacon (Y C , Y H and Y E ) on the glycemia of diabetic and nondiabetic rats fasted for 15 h, treated orally for 14 days with a dose of 400 mg/kg body weight, is shown in Figure 1A and 1B.
The groups of nondiabetic rats treated with the aqueous extracts, extracted with cold water (Y C ) or hot water (Y H ), did not show a change in glycemia (Y C = 111.3±4.9 and Y H = 138.5±7.7 mg/dL) compared to the control group (106.3±3.5 mg/dL). However, treatment of the nondiabetic rats with the hydro-ethanolic extract (Y E ) significantly reduced (28%) the glycemia of the animals (Y E = 76.1±6.7). The results are shown in Figure 1A .
The glycemia of the diabetic rats was 182.9±15.4 mg/dL, i.e., 72% higher than that of the nondiabetic rats ( Figure 1B) . Treatment of the diabetic animals with the Y C or Y H did not change the plasma glucose concentration (Y C = 192.3±5.7 and Y H = 191.7±7.7 mg/dL). However, treatment with Y E significantly (59%) reduced the glycemia of the diabetic rats (Y E = 108.24±9.7), which reverted to normal levels (Figure 1B).
Considering that only the hydro-ethanolic extract of yacon, at the concentration used, was capable of reducing the glucose levels of the diabetic and nondiabetic animals, the subsequent experiments were performed using only Y E .
Treatment of the diabetic and nondiabetic rats with Y E , for different periods of time, showed that a significant reduction of glycemia occurred only in the 14-day treatment period. The results are shown in Figure 2A and 2B.
Effect of the hydro-ethanolic extract of yacon on the consumption of food and water, volume of urine, and body weight of diabetic and nondiabetic rats
To investigate whether the reduction of glycemia observed in the previous experiment is related to lower food intake of the animals, an experiment was performed to evaluate the food consumption of diabetic and nondiabetic control rats, treated with Y E . Simultaneously, the consumption of water, urine volume, and body weight of the animals, which were maintained in a metabolic cages for 14 days, were evaluated.
As shown in Table I and Figure 3 , there were significant differences in all the parameters evaluated (consumption of water and food, urine volume, and weight gain) between the groups of diabetic (D) and nondiabetic FIGURE 1 -Effect of crude extracts of yacon leaves on glycemia of nondiabetic rats (A) and diabetic rats (B) fasted for 15 h. The animals were treated orally with the different extracts in a single daily dose (400 mg/kg body weight), for 14 days. Y C : aqueous extract of yacon leaves, cold extraction; Y H : aqueous extract of yacon leaves, hot extraction; Y E : hydro-ethanolic extract of yacon. The results represent the mean ± S.E.M. of 5-10 animals per group. *P < 0.05 compared to the control group of nondiabetic rats (N); **p < 0.01 compared to the control group of diabetic animals (D). (ANOVA followed by Tukey's test).
FIGURE 2 -Effect of hydro-ethanolic extract of yacon (Y E ), administered orally at the dose of 400 mg/kg body weight, on the glycemia of nondiabetic rats (A) and diabetic rats (B) after different periods of treatment. The results represent the mean ± S.E.M. of 5-10 animals per group. *P < 0.05 compared to the control group of nondiabetic rats (N); **p < 0.01 compared to the control group of diabetic animals (D). (ANOVA followed by Tukey's test).
(N) animals. The food consumption of the diabetic rats increased approximately 25%, although these animals gained less weight (weight gain = 45.0 g) compared to the group of nondiabetic animals (weight gain = 61.3 g).
Treatment of the diabetic and nondiabetic animals with Y E did not change their consumption of food and water or the urine volume, compared to the respective groups of animals treated only with water (control). Nevertheless, treatment with the extract returned the weight gain of the diabetic rats (weight gain = 59.2 g) to a level similar to the group of nondiabetic rats (weight gain = 57.3 g). The results are shown in Figure 3 .
Effect of hydro-ethanolic extract of yacon on the elevation of glycemia induced by oral administration of amylose or glucose
Another explanation for the reduction of plasma glucose levels, observed in the animals treated with the extract, is that there was interference in the intestinal absorption of carbohydrates. As shown in Figure 4 , in contrast to the effect of acarbose, treatment of the nondiabetic animals with the extract did not inhibit the elevation of glucose levels caused by the amylose. The same was observed when the assays were done using a glucose solution instead of amylose ( Figure 5 ).
Effect of the hydro-ethanolic extract of yacon on the activity of transaminases and alkaline phosphatase in rat plasma
Figures 6A, 6B, and 6C show the activity of AST, ALT, and ALP in the plasma of diabetic and nondiabetic FIGURE 4 -Glycemia, after 30 minutes, of nondiabetic rats that received, orally, water (N), amylose (1 g/kg body weight), amylose (1 g/kg body weight) + Y E (400 mg/kg body weight), or amylose (1 g/kg body weight) + acarbose (10 mg/kg body weight). Each point represents the mean ± S.E.M. of 5 animals per group. *P < 0.05 compared to the control group of nondiabetic rats (N); **p < 0.05 compared to the group of rats that received amylose (ANOVA followed by Tukey's test).
rats. The activity of these enzymes was significantly increased in the plasma of the diabetic rats (D) compared to the nondiabetic rats (N). The oral treatment of nondiabetic rats with the Y E for 14 days did not alter the activity of the enzymes. The treatment of the diabetic rats resulted in normalization of the activity of the enzymes AST, ALT, and ALP.
Effect of the hydro-ethanolic extract of the yacon on plasma creatinine
The concentration of creatinine in plasma was not altered in the diabetic rats compared to the nondiabetic rats. Oral administration of Y E in diabetic (D) and nondiabetic (N) rats for 14 days, did not change the concentration of plasma creatinine. The results are shown in Figure 6D .
Acute toxicity of the hydro-ethanolic of yacon
The acute toxicity of the hydro-ethanolic extract of yacon, administered orally, was low in the mice. No deaths or other adverse effects (change in behavior, posture, exploratory movements, convulsions, abdominal contortions) were observed at doses up to 5000 mg/kg.
DISCUSSION
The present study investigated the effect of crude extracts of yacon leaves (aqueous/cold extraction-Y C and hot-Y H , and hydro-ethanolic -Y E ), on glycemia of fasting diabetic and non-diabetic rats. Streptozotocin -STZ (50 mg/kg body weight) administered intraperitoneally in rats, effectively FIGURE 6 -Effect of the hydro-ethanolic extract of yacon on the activity of aspartate aminotransferase -AST (A), alanine aminotransferase -ALT (B), alkaline phosphatase -ALP (C) and creatinine (D) of nondiabetic rats (N) and diabetic rats (D) fasted for 15 hours. The animals were treated with Y E for 14 days, orally, at the dose of 400 mg/kg body weight. Each bar represents the mean ± S.E.M. of 6 animals. *P < 0.05 compared to the control group of nondiabetic rats. **P < 0.05 compared to the control group of diabetic rats (ANOVA followed by Tukey's test).
FIGURE 5 -Glycemia of nondiabetic rats that received orally, upload glucose (1 g/kg body weight) + water (N) or upload glucose (1 g/kg body weight) + Y E (400 mg/kg body weight) (N+ Y E ). Each point represents the mean ± S.E.M. of 6 animals per group.
induced diabetes, as observed by the elevation of glycemia, polyphagy, polydipsia, and loss of body weight of the animals compared to nondiabetic rats.
The Y E administered orally at the dose of 400 mg/kg body weight for 14 days, significantly reduced the levels of blood glucose of the diabetic rats (59%) and nondiabetic rats (28%). This effect was not observed when the crude aqueous extracts of yacon (Y C and Y H ), prepared in the same concentration (10%), and administered in the same dosage were used.
These results complement those of Aybar et al. (2001) , who observed that tea made from an infusion of yacon leaves, administered orally for 30 days, reduced glycemia in diabetic rats by about 27%. According to these investigators, the inhibitory action of this preparation on STZ-induced hyperglycemia can be attributed to the fact of this plant induces an increase in the concentration of plasma insulin.
According to Simonovska et al. (2003) , the solvent used in the preparation of plant extracts can qualitatively and/or quantitatively affect the biologically active chemical constituents extracted. Therefore, the results indicate that the form of preparation of the extract is very important for its biological activity, and that probably the active principles responsible for the effect of the extract obtained from yacon leaves on glycemia of rats are extracted better with an organic solvent.
It is important to emphasize that the effect of the extract on the glycemia of rats was only observed after 14 days of treatment, indicating that the actives substances requires a certain period of time to reach effective concentrations in the organism. Similar results were reported by other investigators, who observed that some plant extracts show hypoglycemiant activity only after a more prolonged period of administration (Mohammed-AliAjabnoor, 1990; Roman-Ramos, 1991; Alarcon-Aguilara, 1998; Aybar et al., 2001) .
There are several possibility for the mechanisms by which the plant reduces blood glucose concentration: increased release of insulin through stimulation of the β-pancreatic cells, resistance to the hormones that increase the rate of glucose release, increase of the number and sensitivity of the insulin receptors, decreased release glycogen degradation, increase in glucose uptake by tissues and organs, and reduction of the intestinal absorption of glucose, among others (cited in the revision of Negri, 2005) .
Although it is not possible to establish the exact mechanism of action of the Y E from the data of the present study, it was clearly demonstrated that the inhibitory effect on the hyperglycemia of diabetic rats is not related to reduction of food intake or to interference of the extract with the intestinal absorption of carbohydrates.
Additionally, it was observed that the activity of the transaminases (AST and ALT) and alkaline phosphatase (ALP) was increased in the plasma of the diabetic rats, which is consistent with the results of other investigators (Mori et al., 2003; Prakasam et al., 2004; Hwang et al., 2005) . These manifestations are a consequence of a metabolic alteration, with an increase of glyconeogenesis and of cetogenesis and/or of hepatic lesions that occur in diabetic animals (Mori et al., 2003) .
Treatment of the diabetic rats with the Y E reversed the activity of the enzymes AST, ALT, and ALP to values near to those of nondiabetic rats. One explanation for this is that treatment with the Y E may suppress the hepatocellular lesions induced by the disease itself, suggesting that the reduction of glycemia in the diabetic rats does not result from hepatic toxicity induced by the extract.
Finally, it must be considered that the diabetic animals treated with the Y E showed improvement in weight gain compared to the diabetic rats that did not receive the treatment. These data confirms the antidiabetogenic effect of the extract, since the diabetic state is associated with a lower weight gain, or loss of weight of the animals (Maiti et al., 2004) .
Oral administration of Y E in doses up to 5000 mg/kg body weight did not cause acute toxicity in the animals, indicating that the margin of safety of this extract is quite high. Daily treatment with Y E at the dose of 400 mg/kg body weight, orally for 14 days, did not cause mortality or other signs of toxicity. Genta et al. (2005) described similar results, although they used an extract of yacon roots administered orally to the animals.
In summary, the present study provided evidence indicating that the hydro-ethanolic extract of yacon significantly reduces the levels of glucose in diabetic rats. In addition, treatment with the extract causes the recovery of certain altered biochemical parameters and of the body weight of diabetic animals. This being so, these results justify the development of additional pharmacological and biochemical studies in order to clarify the nature of the compounds responsible for the effect and the exact mechanism of action of these compounds. 
RESUMO
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